Comparative Pharmacology
Head-to-head clinical analysis: AMOXAPINE versus IMIPRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXAPINE versus IMIPRAMINE HYDROCHLORIDE.
AMOXAPINE vs IMIPRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their synaptic concentrations. Also has anticholinergic, antihistaminergic, and alpha-1 adrenergic blocking effects.
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
Initial 75 mg/day orally in divided doses, increase to 150-200 mg/day; maximum 300 mg/day. For maintenance, 50-150 mg/day orally.
None Documented
None Documented
Clinical Note
moderateAmoxapine + Budesonide
"The therapeutic efficacy of Budesonide can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone furoate
"The therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Fluticasone propionate."
Clinical Note
moderateParent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Terminal half-life 11-25 hours (mean ~20 h); clinical context: steady-state achieved in ~1 week, dosing adjustment needed in hepatic impairment
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
Renal (70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
Amoxapine + Desmopressin
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin."